Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 222

1.

Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study.

Kristensen LE, Petersson IF, Geborek P, Jöud A, Saxne T, Jacobsson LT, Englund M.

Rheumatology (Oxford). 2012 Feb;51(2):243-9. doi: 10.1093/rheumatology/ker169. Epub 2011 May 12.

PMID:
21565900
2.

Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.

Kristensen LE, Englund M, Neovius M, Askling J, Jacobsson LT, Petersson IF.

Ann Rheum Dis. 2013 Oct;72(10):1675-9. doi: 10.1136/annrheumdis-2012-202229. Epub 2012 Nov 12.

PMID:
23148309
3.

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.

Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.

Arthritis Res Ther. 2011 Jun 20;13(3):R94. doi: 10.1186/ar3369.

4.
5.

Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.

Paccou J, Baclé-Boutry MA, Solau-Gervais E, Bele-Philippe P, Flipo RM.

J Rheumatol. 2012 Jul;39(7):1418-23. doi: 10.3899/jrheum.111337. Epub 2012 Jun 15.

PMID:
22707611
6.

Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice.

Neovius M, Simard JF, Klareskog L, Askling J; ARTIS Study Group.

Ann Rheum Dis. 2011 Aug;70(8):1407-14. doi: 10.1136/ard.2010.144139. Epub 2011 Apr 25.

PMID:
21518724
7.

Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.

Bonafede MM, Gandra SR, Fox KM, Wilson KL.

J Med Econ. 2012;15(4):635-43. doi: 10.3111/13696998.2012.667028. Epub 2012 Mar 1.

PMID:
22332705
8.

Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis.

Keat AC, Gaffney K, Gilbert AK, Harris C, Leeder J.

Rheumatology (Oxford). 2008 Apr;47(4):481-3. doi: 10.1093/rheumatology/ken010. Epub 2008 Feb 16.

PMID:
18281690
9.

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

Ollendorf DA, Klingman D, Hazard E, Ray S.

Clin Ther. 2009 Apr;31(4):825-35. doi: 10.1016/j.clinthera.2009.04.002.

PMID:
19446156
10.

Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study.

Olofsson T, Englund M, Saxne T, Jöud A, Jacobsson LT, Geborek P, Allaire S, Petersson IF.

Ann Rheum Dis. 2010 Dec;69(12):2131-6. doi: 10.1136/ard.2009.127852. Epub 2010 Aug 6.

PMID:
20693274
11.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

12.

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.

Arthritis Rheum. 2009 Nov;60(11):3180-9. doi: 10.1002/art.24941.

13.

Risk factors for disability pension in a population-based cohort of men and women on long-term sick leave in Sweden.

Karlsson NE, Carstensen JM, Gjesdal S, Alexanderson KA.

Eur J Public Health. 2008 Jun;18(3):224-31. doi: 10.1093/eurpub/ckm128. Epub 2008 Feb 1.

PMID:
18245150
14.
15.

Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.

Bonafede M, Fox KM, Watson C, Princic N, Gandra SR.

Adv Ther. 2012 Aug;29(8):664-74. doi: 10.1007/s12325-012-0037-5. Epub 2012 Aug 8.

PMID:
22886712
16.

Mortality rates in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: drug-specific comparisons in the Swedish Biologics Register.

Simard JF, Neovius M, Askling J; ARTIS Study Group.

Arthritis Rheum. 2012 Nov;64(11):3502-10. doi: 10.1002/art.34582.

17.

The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.

Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S.

Int J Rheum Dis. 2009 Jul;12(2):118-24. doi: 10.1111/j.1756-185X.2009.01393.x.

PMID:
20374328
18.

Investigation of effects of two-different treatment modalities on nerve conduction in patients with ankylosing spondylitis.

Capkin E, Karkucak M, Kose MM, Çakmak VA, Turkyilmaz AK, Tosun M.

Rheumatol Int. 2012 Feb;32(2):431-4. doi: 10.1007/s00296-010-1677-x. Epub 2010 Dec 1.

PMID:
21120488
19.

Patients with ankylosing spondylitis have increased sick leave--a registry-based case-control study over 7 yrs.

Strömbeck B, Jacobsson LT, Bremander A, Englund M, Heide A, Turkiewicz A, Petersson IF.

Rheumatology (Oxford). 2009 Mar;48(3):289-92. doi: 10.1093/rheumatology/ken497. Epub 2009 Jan 22.

20.

Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).

Virkki LM, Valleala H, Takakubo Y, Vuotila J, Relas H, Komulainen R, Koivuniemi R, Yli-Kerttula U, Mali M, Sihvonen S, Krogerus ML, Jukka E, Nyrhinen S, Konttinen YT, Nordström DC.

Clin Rheumatol. 2011 Nov;30(11):1447-54. doi: 10.1007/s10067-011-1779-1. Epub 2011 Jun 7.

PMID:
21644062

Supplemental Content

Support Center